Keyword: Enrique Conterno
New FibroGen CEO and former Eli Lilly vet, Enrique Conterno, cleared some existing investor doubts about roxadustat's potential.
Lilly's top U.S. executive is on his way out. Enrique Conterno, who also heads up Lilly's global diabetes business, will step down at year's end.
Lilly analysts worry growth could suffer if it doesn't win a nod for both baricitinib doses—and an FDA panel shot down one of them Monday.
Eli Lilly says it isn't afraid of new competition to diabetes drug Trulicity from Novo Nordisk’s newly launched weekly GLP-1, Ozempic.
With more than 2,000 early retirements settled, Eli Lilly says it's "on track" to hit its goal of cutting 3,500 jobs by year's end.
At Eli Lilly, the new year comes with a shakeup in its commercial organization, with vet Enrique Conterno taking the reins in the U.S. and ex-Novartis exec Christi Shaw joining as head of Bio-Medicines.
Insulin list prices have skyrocketed in recent years--but it’s not drugmakers reaping the increases, they say. That would be PBMs, the latest villain in the ongoing U.S. drug-pricing debate.